Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an update.
RemeGen Co., Ltd. announced the purchase of a principal-guaranteed wealth management product worth RMB350.0 million from CMB Yantai Branch, using idle self-owned funds. This transaction, approved by the Board, is considered a discloseable transaction under Hong Kong’s Listing Rules, reflecting the company’s strategic cash management approach to optimize returns on its idle funds.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology and pharmaceutical industry. The company is primarily focused on developing innovative drugs and therapies, with a market focus on leveraging its proprietary technology to address unmet medical needs.
Average Trading Volume: 11,729,185
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.92B
For a thorough assessment of 9995 stock, go to TipRanks’ Stock Analysis page.